Multiple myeloma

Cover Page

Cite item

Full Text

About the authors

Larisa P. Mendeleeva

National Research Center for Hematology

Author for correspondence.
Email: or@hpmp.ru
ORCID iD: 0000-0002-4966-8146

D. Sci. (Med.)

Russian Federation, Moscow

Olga M. Votiakova

Blokhin National Medical Research Center of Oncology

Email: or@hpmp.ru

Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology

Russian Federation, Moscow

Irina G. Rekhtina

National Research Center for Hematology

Email: or@hpmp.ru

D. Sci. (Med.), National Research Center for Hematology

Russian Federation, Moscow

Evgenii A. Osmanov

Blokhin National Medical Research Center of Oncology; Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

D. Sci. (Med.), Prof., Blokhin National Medical Research Center of Oncology, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Irina V. Poddubnaya

Russian Medical Academy of Continuous Professional Education

Email: or@hpmp.ru
ORCID iD: 0000-0002-0995-1801

D. Sci. (Med.), Prof., Acad. RAS, Russian Medical Academy of Continuous Professional Education

Russian Federation, Moscow

Liudmila Iu. Grivtsova

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

Cand. Sci. (Med.), D. Sci. (Biol.), Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Obninsk

Natalia A. Falaleeva

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

D. Sci. (Med.), Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Obninsk

Vadim V. Baikov

Pavlov First Saint Petersburg State Medical University

Email: or@hpmp.ru

D. Sci. (Med.), Prof., Pavlov First Saint Petersburg State Medical University

Russian Federation, Saint Petersburg

Alla M. Kovrigina

National Research Center for Hematology; Academy of Postgraduate Education

Email: or@hpmp.ru

D. Sci. (Biol.), Prof., Academy of Postgraduate Education, National Research Center for Hematology

Russian Federation, Moscow

Aleksei A. Nevol’skikh

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

D. Sci. (Med.), Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Obninsk

Sergei A. Ivanov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

D. Sci. (Med.), Prof. RAS, Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Obninsk

Zhanna V. Khailova

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

Cand. Sci. (Med.), Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Obninsk

Tigran G. Gevorkian

Blokhin National Medical Research Center of Oncology

Email: or@hpmp.ru

deputy director, Blokhin National Medical Research Center of Oncology

Russian Federation, Moscow

References

  1. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М., 2018; с. 213–41. [Mendeleeva L.P., Votiakova O.M., Rekhtina I.G. Multiple myeloma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V. Poddubnaya, V.G. Savchenko. Moscow, 2018; p. 213–41 (in Russian).]
  2. Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol 2015; 20 (3): 413–22.
  3. Lewis EB. Leukemia, Multiple Myeloma, and Aplastic Anemia in American Radiologists. Science (80-.) 1963; 142 (3598): 1492–4.
  4. Linet MS, Harlow SD, McLaughlin JK. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. Cancer Res. 1987; 47 (11): 2978–81.
  5. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91 (1): 3–21.
  6. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122 (10): 3456–63.
  7. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12 (5): 335–48.
  8. Fonseca R et al. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review. Leukemia 2009; 23 (12): 2210–21.
  9. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. [Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. A.D. Kaprina, V.V. Starinsky, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018 (in Russian).]
  10. Бессмельцев С.С. Множественная миелома (лекция). Вестн. гематологии. 2014; 10 (3): 6–39. [Bessmel’tsev S.S. Mnozhestvennaia mieloma (lektsiia). Vestn. gematologii. 2014; 10 (3): 6–39 (in Russian).]
  11. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36 (3): 842–54.
  12. Greipp PR et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23 (15): 3412–20.
  13. Palumbo A et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol Am Soc Clin Oncol 2015; 33 (26): 2863–9.
  14. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23 (1): 3–9.
  15. Moreau P et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2017; 28 (Suppl. 4): iv52–iv61.
  16. Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15 (12): e538–e548.
  17. Coppola A et al. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 2011; 37 (8): 929–45.
  18. Tripathy S. The role of serum protein electrophoresis in the detection of multiple myeloma: An experience of a corporate hospital. J Clin Diagnostic Res 2012; 6 (9): 1458–61.
  19. Misra A et al. Old but Still Relevant: High Resolution Electrophoresis and Immunofixation in Multiple Myeloma. Ind J Hematol Blood Transfusion 2016; 32 (1): 10–7.
  20. Любимова Н.В. и др. Свободные легкие цепи иммуноглобулинов в диагностике и прогнозе множественной миеломы. Альманах клин. медицины. 2017; 45 (2): 102–8. [Liubimova N.V. et al. Svobodnye legkie tsepi immunoglobulinov v diagnostike i prognoze mnozhestvennoi mielomy. Al’manakh klin. meditsiny. 2017; 45 (2): 102–8 (in Russian).]
  21. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138 (5): 563–79.
  22. Julie D et al. Comparison of Bone marrow Aspirate and Bone marrow Biopsy in the workup of Patients with Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2015; 15: e117.
  23. Pianko MJ et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clinl Cancer Res 2014; 20 (23): 5888–97.
  24. Cavo M et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18 (4): e206–e217.
  25. Mateos M-V, San Miguel J. V. Smoldering multiple myeloma. Hematol Oncol 2015; 33: 33–7.
  26. Zou Y et al. Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leuk Lymphoma 2014; 55 (9): 2024–31.
  27. Mateos MV et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28 (13): 2259–66.
  28. Bringhen S et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116 (23): 4745–53.
  29. Takezako N et al. The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients. Blood 2016; 128 (22).
  30. Jagannath S et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009; 146 (6): 619–26.
  31. Weisel K et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk Lymphoma 2017; 58 (1): 153–61.
  32. Benboubker L et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371 (10): 906–17.
  33. Facon T. et al. Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM). Clin Lymphoma Myeloma Leuk 2015; 15: e134.
  34. Palumbo A et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366 (19): 1759–69.
  35. Mateos MV et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018; 378 (6): 518–28.
  36. Su B et al. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Leuk Lymphoma 2018.
  37. Dhakal B et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction a systematic review and meta-analysis. JAMA 2018; 4 (3): 343–50.
  38. Nooka AK et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients. Cancer 2013; 119 (23): 4119–28.
  39. Leiba M et al. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis. Br J Haematol 2014; 166 (5): 702–10.
  40. Tuchman SA, Chao NJ, Gasparetto CG. Lenalidomide before and after autologous hematopoietic stem cell transplantation in multiple myeloma. Advanc Hematol 2012; 2012.
  41. Knop S et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113 (18): 4137–43.
  42. Reece DE et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Br J Haematol 2015; 168 (1): 46–54.
  43. Fung HC, Nathan S, Maciejewski JJ. Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter? Clin Pharmacol 2010; 2: 71–5.
  44. Tuchman SA et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher 2015; 30 (3): 176–82.
  45. Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012; 904: 37–47.
  46. Sivaraj D et al. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 2018; 53 (1): 34–8.
  47. Oliva S et al. Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients: A prospective analysis. Oncotarget 2017; 8 (4): 5924–35.
  48. Sonneveld P et al. Consolidation followed by maintenance vs. maintenance alone in newly diagnosed, transplant eligible multiple myeloma: a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM TRIAL). EHA 23 Proceedings. 2018. Abstract S108.
  49. Roussel M et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol 2014; 32 (25): 2712–7.
  50. Naumann-Winter F et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012; 10: CD004626.
  51. Nathwani N, Larsen JT, Kapoor P. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Cur Hematol Malig Rep 2016; 11 (2): 127–36.
  52. Sonneveld P et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012; 30 (24): 2946–55.
  53. McCarthy PL et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366 (19): 1770–81.
  54. Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366 (19): 1782–91.
  55. Palumbo A et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371 (10): 895–905.
  56. Beurden-Tan CHYV et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol Am Soc Clin Oncol 2017; 35 (12): 1312–9.
  57. Knopf KB et al. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2014; 14 (5): 380–8.
  58. Scott K et al. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev 2016; 4: CD010816.
  59. Dimopoulos MA et al. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clin Lymphoma Myeloma Leuk 2018; 18 (3): 163–173.e6.
  60. Anderson KC et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. J Clin Oncol 2009; 27 (15). Suppl. Abstract 8536.
  61. Shah C. et al. Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: Systematic review and meta- analysis of 14 trials.Oncotarget 2018; 9 (34): 23704–17.
  62. Moreau P et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 374 (17): 1621–34.
  63. Miguel JS et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14 (11): 1055–66.
  64. Lokhorst HM et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015; 373 (13): 1207–19.
  65. Lonial S et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 2016; 387 (10027): 1551–60.
  66. Tsang RW et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 101 (4): 794–808.
  67. Mark D et al. Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine. Front Oncol 2019; 9: 601.
  68. Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 502–11. [Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol’nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).]
  69. Compagno N et al. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Fron Immunol 2014; 5: 626.
  70. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 289–311. [Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 289–311 (in Russian).]
  71. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016. [Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I. Pirogova Minzdrava Rossii, 2016 (in Russian).]
  72. Durie BGM et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20 (9): 1467–73.
  73. Rajkumar SV et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117 (18): 4691–5.
  74. Kumar S et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17 (8): e328–e346.
  75. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5). Suppl 1; p. S88–94.
  76. Jones JR et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J 2016; 6 (12): e506.
  77. Rajkumar SV et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11 (1): 29–37.
  78. Punke AP, Waddell JA, Solimando DA. Lenalidomide, bortezomib, and dexamethasone (RVD) regimen for multiple myeloma. Hosp Pharm 2017; 52 (1): 27–32.
  79. Dimopoulos MA etМенделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М., 2018; с. 213–41. [Mendeleeva L.P., Votiakova O.M., Rekhtina I.G. Multiple myeloma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V. Poddubnaya, V.G. Savchenko. Moscow, 2018; p. 213–41 (in Russian).]
  80. Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol 2015; 20 (3): 413–22.
  81. Lewis EB. Leukemia, Multiple Myeloma, and Aplastic Anemia in American Radiologists. Science (80-.) 1963; 142 (3598): 1492–4.
  82. Linet MS, Harlow SD, McLaughlin JK. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. Cancer Res. 1987; 47 (11): 2978–81.
  83. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91 (1): 3–21.
  84. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122 (10): 3456–63.
  85. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12 (5): 335–48.
  86. Fonseca R et al. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review. Leukemia 2009; 23 (12): 2210–21.
  87. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. [Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. A.D. Kaprina, V.V. Starinsky, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018 (in Russian).]
  88. Бессмельцев С.С. Множественная миелома (лекция). Вестн. гематологии. 2014; 10 (3): 6–39. [Bessmel’tsev S.S. Mnozhestvennaia mieloma (lektsiia). Vestn. gematologii. 2014; 10 (3): 6–39 (in Russian).]
  89. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36 (3): 842–54.
  90. Greipp PR et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23 (15): 3412–20.
  91. Palumbo A et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol Am Soc Clin Oncol 2015; 33 (26): 2863–9.
  92. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23 (1): 3–9.
  93. Moreau P et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2017; 28 (Suppl. 4): iv52–iv61.
  94. Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15 (12): e538–e548.
  95. Coppola A et al. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 2011; 37 (8): 929–45.
  96. Tripathy S. The role of serum protein electrophoresis in the detection of multiple myeloma: An experience of a corporate hospital. J Clin Diagnostic Res 2012; 6 (9): 1458–61.
  97. Misra A et al. Old but Still Relevant: High Resolution Electrophoresis and Immunofixation in Multiple Myeloma. Ind J Hematol Blood Transfusion 2016; 32 (1): 10–7.
  98. Любимова Н.В. и др. Свободные легкие цепи иммуноглобулинов в диагностике и прогнозе множественной миеломы. Альманах клин. медицины. 2017; 45 (2): 102–8. [Liubimova N.V. et al. Svobodnye legkie tsepi immunoglobulinov v diagnostike i prognoze mnozhestvennoi mielomy. Al’manakh klin. meditsiny. 2017; 45 (2): 102–8 (in Russian).]
  99. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138 (5): 563–79.
  100. Julie D et al. Comparison of Bone marrow Aspirate and Bone marrow Biopsy in the workup of Patients with Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2015; 15: e117.
  101. Pianko MJ et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clinl Cancer Res 2014; 20 (23): 5888–97.
  102. Cavo M et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18 (4): e206–e217.
  103. Mateos M-V, San Miguel J. V. Smoldering multiple myeloma. Hematol Oncol 2015; 33: 33–7.
  104. Zou Y et al. Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leuk Lymphoma 2014; 55 (9): 2024–31.
  105. Mateos MV et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28 (13): 2259–66.
  106. Bringhen S et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116 (23): 4745–53.
  107. Takezako N et al. The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients. Blood 2016; 128 (22).
  108. Jagannath S et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009; 146 (6): 619–26.
  109. Weisel K et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk Lymphoma 2017; 58 (1): 153–61.
  110. Benboubker L et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371 (10): 906–17.
  111. Facon T. et al. Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM). Clin Lymphoma Myeloma Leuk 2015; 15: e134.
  112. Palumbo A et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366 (19): 1759–69.
  113. Mateos MV et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018; 378 (6): 518–28.
  114. Su B et al. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Leuk Lymphoma 2018.
  115. Dhakal B et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction a systematic review and meta-analysis. JAMA 2018; 4 (3): 343–50.
  116. Nooka AK et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients. Cancer 2013; 119 (23): 4119–28.
  117. Leiba M et al. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis. Br J Haematol 2014; 166 (5): 702–10.
  118. Tuchman SA, Chao NJ, Gasparetto CG. Lenalidomide before and after autologous hematopoietic stem cell transplantation in multiple myeloma. Advanc Hematol 2012; 2012.
  119. Knop S et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113 (18): 4137–43.
  120. Reece DE et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Br J Haematol 2015; 168 (1): 46–54.
  121. Fung HC, Nathan S, Maciejewski JJ. Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter? Clin Pharmacol 2010; 2: 71–5.
  122. Tuchman SA et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher 2015; 30 (3): 176–82.
  123. Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012; 904: 37–47.
  124. Sivaraj D et al. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 2018; 53 (1): 34–8.
  125. Oliva S et al. Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients: A prospective analysis. Oncotarget 2017; 8 (4): 5924–35.
  126. Sonneveld P et al. Consolidation followed by maintenance vs. maintenance alone in newly diagnosed, transplant eligible multiple myeloma: a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM TRIAL). EHA 23 Proceedings. 2018. Abstract S108.
  127. Roussel M et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol 2014; 32 (25): 2712–7.
  128. Naumann-Winter F et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012; 10: CD004626.
  129. Nathwani N, Larsen JT, Kapoor P. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Cur Hematol Malig Rep 2016; 11 (2): 127–36.
  130. Sonneveld P et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012; 30 (24): 2946–55.
  131. McCarthy PL et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366 (19): 1770–81.
  132. Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366 (19): 1782–91.
  133. Palumbo A et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371 (10): 895–905.
  134. Beurden-Tan CHYV et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol Am Soc Clin Oncol 2017; 35 (12): 1312–9.
  135. Knopf KB et al. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2014; 14 (5): 380–8.
  136. Scott K et al. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev 2016; 4: CD010816.
  137. Dimopoulos MA et al. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clin Lymphoma Myeloma Leuk 2018; 18 (3): 163–173.e6.
  138. Anderson KC et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. J Clin Oncol 2009; 27 (15). Suppl. Abstract 8536.
  139. Shah C. et al. Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: Systematic review and meta- analysis of 14 trials.Oncotarget 2018; 9 (34): 23704–17.
  140. Moreau P et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 374 (17): 1621–34.
  141. Miguel JS et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14 (11): 1055–66.
  142. Lokhorst HM et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015; 373 (13): 1207–19.
  143. Lonial S et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 2016; 387 (10027): 1551–60.
  144. Tsang RW et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 101 (4): 794–808.
  145. Mark D et al. Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine. Front Oncol 2019; 9: 601.
  146. Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 502–11. [Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol’nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).]
  147. Compagno N et al. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Fron Immunol 2014; 5: 626.
  148. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 289–311. [Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 289–311 (in Russian).]
  149. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016. [Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I. Pirogova Minzdrava Rossii, 2016 (in Russian).]
  150. Durie BGM et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20 (9): 1467–73.
  151. Rajkumar SV et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117 (18): 4691–5.
  152. Kumar S et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17 (8): e328–e346.
  153. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5). Suppl 1; p. S88–94.
  154. Jones JR et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J 2016; 6 (12): e506.
  155. Rajkumar SV et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11 (1): 29–37.
  156. Punke AP, Waddell JA, Solimando DA. Lenalidomide, bortezomib, and dexamethasone (RVD) regimen for multiple myeloma. Hosp Pharm 2017; 52 (1): 27–32.
  157. Dimopoulos MA et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18 (10): 1327–37.
  158. Dadacaridou M et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 2007; 12 (1): 41–4.
  159. Lakshman A et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol 2018; 93 (2): 179–86.
  160. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
  161. al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18 (10): 1327–37.
  162. Dadacaridou M et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 2007; 12 (1): 41–4.
  163. Lakshman A et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol 2018; 93 (2): 179–86.
  164. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. The induction therapy algorithm

Download (150KB)
Indexing metadata
3. Treatment algorithm for the relapse of multiple myeloma

Download (33KB)
Indexing metadata

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies